SONN icon

Sonnet BioTherapeutics
SONN

Overview Fund Activity

24 hedge funds and large institutions have $2.26M invested in Sonnet BioTherapeutics in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 3 closing their positions.

Holders
24
Holders Change
+4
Holders Change %
+20%
% of All Funds
0.38%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
6
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Renaissance Technologies
1
Renaissance Technologies
New York
$677K
2
Citadel Advisors
2
Citadel Advisors
Florida
$153K
3
Millennium Management
3
Millennium Management
New York
$147K
4
Susquehanna International Group
4
Susquehanna International Group
Pennsylvania
$77K
5
CAM
5
Campion Asset Management
Virginia
$34K

Top Sellers

1
Geode Capital Management
1
Geode Capital Management
Massachusetts
$250K
2
VF
2
Virtu Financial
New York
$42K
3
Vanguard Group
3
Vanguard Group
Pennsylvania
$632K
4
T. Rowe Price Associates
4
T. Rowe Price Associates
Maryland
$0
5
BPA
5
Beacon Pointe Advisors
California
$0
Name Market Value Shares Shares
Change 		Shares
Change %
Morgan Stanley
26
Morgan Stanley
New York
$0 1,278 – –
Bank of America
27
Bank of America
North Carolina
$0 38 – –
Wells Fargo
28
Wells Fargo
California
$0 349 +14 +4%
1
2